Patents by Inventor Jesus E. Gonzalez, III

Jesus E. Gonzalez, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8426201
    Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: April 23, 2013
    Assignee: Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Michael P. Maher, Jesus E. Gonzalez, III
  • Patent number: 8324220
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: December 4, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Mitchell Wilson, Esther Ann Martinborough, Timothy Donald Neubert, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Hilgraf
  • Patent number: 8309543
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: November 13, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jesus E. Gonzalez, III, Andreas P. Termin, Esther Martinborough, Nicole Hilgraf
  • Publication number: 20120238578
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: May 23, 2012
    Publication date: September 20, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jesus E. Gonzalez, III, Andreas P. Termin, Esther Martinborough, Nicole Zimmerman
  • Publication number: 20120184583
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Application
    Filed: April 4, 2011
    Publication date: July 19, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Frederick F. Van Goor, Sara Sabina Hadida-Ruah, Ashvani Kumar Singh, Eric R. Olson, Lewis Ray Makings, Jesus E. Gonzalez, III, James Arvid Rader, Fred Chambers, III, Mark Thomas Miller, Peter Diederik Jan Grootenhuis, Yahua Liu
  • Publication number: 20120040935
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: May 18, 2011
    Publication date: February 16, 2012
    Applicant: Vertex Pharmaceuticals, Inc.
    Inventors: Dean M. Wilson, Andreas P. Termin, Timothy D. Neubert, Jian Wang, Yulian Zhang, Jesus E. Gonzalez, III, Esther Martinborough, Nicole Zimmerman
  • Patent number: 8071318
    Abstract: Drug candidate screening methods are applied to discover compounds with activity against ion channel targets. The method may include modulating the transmembrane potential of host cells in a plurality of sample wells with a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: December 6, 2011
    Assignee: Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Michael P. Maher, Jesus E. Gonzalez, III
  • Patent number: 7968545
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: June 28, 2011
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Dean M. Wilson, Andreas P. Termin, Timothy D. Neubert, Jian Wang, Yulian Zhang, Jesus E. Gonzalez, III, Esther Martinborough, Nicole Zimmerman
  • Patent number: 7923537
    Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: April 12, 2011
    Assignee: Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Michael P. Maher, Jesus E. Gonzalez, III
  • Publication number: 20110003814
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: September 8, 2010
    Publication date: January 6, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Dean Mitchell Wilson, Esther Martinborough, Timothy Donald Neubert, Andreas Peter Termin, Jesus E. Gonzalez, III, Nicole Zimmerman
  • Patent number: 7816529
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: October 19, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Mitchell Wilson, Esther Martinborough, Timothy Donald Neubert, Andreas Peter Termin, Jesus E. Gonzalez, III, Nicole Zimmerman
  • Patent number: 7767408
    Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: August 3, 2010
    Assignee: Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Michael P. Maher, Jesus E. Gonzalez, III
  • Publication number: 20100160316
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: March 1, 2010
    Publication date: June 24, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jesus E. Gonzalez, III, Dean M. Wilson, Andreas P. Termin, Peter D. J. Grootenhuis, Yulian Zhang, Benjamin J. Petzoldt, Lev Tyler Dewey Fanning, Timothy D. Neubert, Roger D. Tung, Esther Martinborough, Nicole Zimmerman
  • Publication number: 20100144798
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Application
    Filed: August 20, 2009
    Publication date: June 10, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Frederick F. VanGoor, Sara Sabina Hadida Ruah, Ashvani Kumar Singh, Eric R. Olson, Lewis Ray Makings, Jesus E. Gonzalez, III, James Arvid Rader, Fred Chambers, III, Mark Thomas Miller, Peter Diederik Jan Grootenhuis, Yahua Liu
  • Patent number: 7713983
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: May 11, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jesus E. Gonzalez, III, Dean M. Wilson, Andreas P. Termin, Peter D. J. Grootenhuis, Yulian Zhang, Benjamin J. Petzoldt, Lev Tyler Dewey Fanning, Timothy D. Neubert, Roger D. Tung, Esther Martinborough, Nicole Zimmerman
  • Patent number: 7705031
    Abstract: The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R1, Z, Y, RA, and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: April 27, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean M. Wilson, Andreas P. Termin, Jesus E. Gonzalez, III, Nicole Zimmermann, Yulian Zhang, Lev T. D. Fanning
  • Patent number: 7695922
    Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: April 13, 2010
    Assignee: Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Michael P. Maher, Jesus E. Gonzalez, III
  • Publication number: 20100087479
    Abstract: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: September 10, 2009
    Publication date: April 8, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jesus E. Gonzalez, III, Andreas P. Termin, Esther Martinborough, Nicole Zimmerman
  • Publication number: 20100081163
    Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.
    Type: Application
    Filed: September 28, 2009
    Publication date: April 1, 2010
    Applicant: Vertex Pharmaceuticals (San Diego) LLC
    Inventors: Michael P. Maher, Jesus E. Gonzalez, III
  • Patent number: 7687282
    Abstract: Methods and compositions are provided for determining the potential of a membrane. In one aspect, the method comprises: (a) introducing a first reagent comprising a hydrophobic fluorescent ion capable of redistributing from a first face of the membrane to a second face of the membrane in response to changes in the potential of the membrane, as described by the Nernst equation, (b) introducing a second reagent which labels the first face or the second face of the membrane, which second reagent comprises a chromophore capable of undergoing energy transfer by either (i) donating excited state energy to the fluorescent ion, or (ii) accepting excited state energy from the fluorescent ion, (c) exposing the membrane to radiation; (d) measuring energy transfer between the fluorescent ion and the second reagent, and (e) relating the energy transfer to the membrane potential. Energy transfer is typically measured by fluorescence resonance energy transfer.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: March 30, 2010
    Assignee: The Regents of the University of California
    Inventors: Roger Y. Tsien, Jesus E. Gonzalez, III